Radformation, Inc., a leading provider of automation solutions for cancer care, has recently acquired Limbus AI, a prominent supplier of automated contouring software for radiation therapy. This acquisition marks Radformation’s commitment to innovation and expanding its AI-driven capabilities in cancer treatment.
Kurt Sysock, CEO of Radformation, stated the company’s goal to improve the radiation therapy process through efficiency, quality, and patient safety by incorporating Limbus’ technology and expertise into their offerings. By combining the strengths of both companies’ platforms, Radformation aims to push the boundaries of innovative software solutions in radiation therapy even further.
The merger between Radformation and Limbus AI seeks to create the most advanced AI-driven contouring solution currently available. The collaboration is expected to enhance contouring capabilities while also driving innovation, leading to new advancements in radiation therapy.
Karl Otto, CEO of Limbus AI, emphasized the shared vision of both companies in delivering innovative software solutions for patient care. The merger will leverage the talents of both teams to achieve significant progress in the field of radiation therapy.
By combining Radformation’s global presence and extensive product utilization with Limbus AI’s impact on numerous patients worldwide, this acquisition aims to accelerate innovation, extend reach, and improve patient outcomes on a global scale. This collaboration signifies a new era in healthcare technology with the potential to revolutionize cancer care. For more information about this acquisition visit www.radformation.com
